Dự đoán các ứng viên thuốc mới cho các khối u thần kinh nội tiết tụy thông qua so sánh chữ ký gen và lập bản đồ kết nối

Frilling, A.; Akerström, G.; Falconi, M.; Pavel, M.; Ramos, J.; Kidd, M.; Modlin, I.M. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer 2012, 19, R163-185, https://doi.org/10.1530/erc-12-0024. Cives, M.; Strosberg, J.R.J.C.a.c.j.f.c. Gastroenteropancreatic neuroendocrine tumors. 2018, 68, 471–487. Cloyd, J.M.; Poultsides, G.A. The landmark series: pancreatic neuroendocrine tumors. Annals of Surgical Oncology 2021, 28, 1039-1049, https://doi.org/10.1245/s10434-020-09133-x. Cloyd, J.M.; Wiseman, J.T.; Pawlik, T.M. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol 2020, 11, 590-600, https://doi.org/10.21037/jgo.2019.11.02. Cives, M.; Strosberg, J.J.D. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. 2015, 75, 847-858. Pavel, M.E.; Hainsworth, J.D.; Baudin, E.; Peeters, M.; Hörsch, D.; Winkler, R.E.; Klimovsky, J.; Lebwohl, D.; Jehl, V.; Wolin, E.M.J.T.L. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. 2011, 378, 2005–2012. Raymond, E.; Dahan, L.; Raoul, J.-L.; Bang, Y.-J.; Borbath, I.; Lombard-Bohas, C.; Valle, J.; Metrakos, P.; Smith, D.; Vinik, A.J.N.E.J.o.M. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. 2011, 364, 501–513. Yao, J.C.; Phan, A.; Hoff, P.M.; Chen, H.X.; Charnsangavej, C.; Yeung, S.-C.J.; Hess, K.; Ng, C.; Abbruzzese, J.L.; Ajani, J.A.J.J.o.C.O. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. 2008, 26, 1316–1323. Squires, M.H.; Worth, P.J.; Konda, B.; Shah, M.H.; Dillhoff, M.E.; Abdel-Misih, S.; Norton, J.A.; Visser, B.C.; Dua, M.; Pawlik, T.M.; et al. Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors. Pancreas 2020, 49, 355-360, https://doi.org/10.1097/mpa.0000000000001500. Lamb, J.; Crawford, E.D.; Peck, D.; Modell, J.W.; Blat, I.C.; Wrobel, M.J.; Lerner, J.; Brunet, J.-P.; Subramanian, A.; Ross, K.N.J.s. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. 2006, 313, 1929–1935. Wang, Z.; Dai, Z.; Luo, Z.; Zuo, C.J.M. Identification of pyrvinium, an anthelmintic drug, as a novel anti-adipogenic compound based on the gene expression microarray and connectivity map. 2019, 24, 2391. Sadanandam, A.; Wullschleger, S.; Lyssiotis, C.A.; Grötzinger, C.; Barbi, S.; Bersani, S.; Körner, J.; Wafy, I.; Mafficini, A.; Lawlor, R.T.; et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov 2015, 5, 1296-1313, https://doi.org/10.1158/2159-8290.Cd-15-0068. Missiaglia, E.; Dalai, I.; Barbi, S.; Beghelli, S.; Falconi, M.; della Peruta, M.; Piemonti, L.; Capurso, G.; Di Florio, A.; delle Fave, G.; et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010, 28, 245–255, https://doi.org/10.1200/jco.2008.21.5988. Barrett, T.; Wilhite, S.E.; Ledoux, P.; Evangelista, C.; Kim, I.F.; Tomashevsky, M.; Marshall, K.A.; Phillippy, K.H.; Sherman, P.M.; Holko, M.; et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic acids research 2013, 41, D991-995, https://doi.org/10.1093/nar/gks1193. Zhang, X.; Zhang, W.; Jiang, Y.; Liu, K.; Ran, L.; Song, F. Identification of functional lncRNAs in gastric cancer by integrative analysis of GEO and TCGA data. Journal of cellular biochemistry 2019, 120, 17898-17911, https://doi.org/10.1002/jcb.29058. Sun, J.; Huang, J.; Lan, J.; Zhou, K.; Gao, Y.; Song, Z.; Deng, Y.; Liu, L.; Dong, Y.; Liu, X. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer cell international 2019, 19, 264, https://doi.org/10.1186/s12935-019-0986-8. Heidsma, C.M.; Tsilimigras, D.I.; Rocha, F.; Abbott, D.E.; Fields, R.; Poultsides, G.A.; Cho, C.S.; Lopez-Aguiar, A.G.; Kanji, Z.; Fisher, A.V.; et al. Identifying risk factors and patterns for early recurrence of pancreatic neuroendocrine tumors: a multi-institutional study. Cancers (Basel) 2021, 13, https://doi.org/10.3390/cancers13092242. Dong, D.H.; Zhang, X.F.; Lopez-Aguiar, A.G.; Poultsides, G.; Makris, E.; Rocha, F.; Kanji, Z.; Weber, S.; Fisher, A.; Fields, R.; et al. Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. HPB (Oxford) 2020, 22, 215-223, https://doi.org/10.1016/j.hpb.2019.05.020. Fazio, N.; Buzzoni, R.; Baudin, E.; Antonuzzo, L.; Hubner, R.A.; Lahner, H.; WW, D.E.H.; Raderer, M.; Teulé, A.; Capdevila, J.; et al. A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours. Anticancer Res 2016, 36, 713–719. Valle, J.W.; Borbath, I.; Rosbrook, B.; Fernandez, K.; Raymond, E. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncol 2019, 15, 1219-1230, https://doi.org/10.2217/fon-2018-0882. Shimoyama, R.; Hijioka, S.; Mizuno, N.; Ogawa, G.; Kataoka, T.; Katayama, H.; Machida, N.; Honma, Y.; Boku, N.; Hamaguchi, T.; et al. Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). Pancreatology 2020, 20, 1183-1188, https://doi.org/10.1016/j.pan.2020.07.010. Arnold, R.; Rinke, A.; Klose, K.J.; Müller, H.H.; Wied, M.; Zamzow, K.; Schmidt, C.; Schade-Brittinger, C.; Barth, P.; Moll, R.; et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005, 3, 761-771, https://doi.org/10.1016/s1542-3565(05)00481-7. Walter, T.; Malka, D.; Hentic, O.; Lombard-Bohas, C.; Le Malicot, K.; Smith, D.; Ferru, A.; Assenat, E.; Cadiot, G.; Lievre, A.; et al. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study. Dig Liver Dis 2018, 50, 195-198, https://doi.org/10.1016/j.dld.2017.11.020. Ito, T.; Okusaka, T.; Nishida, T.; Yamao, K.; Igarashi, H.; Morizane, C.; Kondo, S.; Mizuno, N.; Hara, K.; Sawaki, A.; et al. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013, 31, 1265-1274, https://doi.org/10.1007/s10637-012-9910-y. Fazio, N.; Kulke, M.; Rosbrook, B.; Fernandez, K.; Raymond, E. Updated efficacy and safety outcomes for patients with well-differentiated pancreatic neuroendocrine tumors treated with sunitinib. Target Oncol 2021, 16, 27-35, https://doi.org/10.1007/s11523-020-00784-0. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. The New England journal of medicine 2008, 358, 1160-1174, https://doi.org/10.1056/NEJMra0707704. Rajaram, P.; Chandra, P.; Ticku, S.; Pallavi, B.K.; Rudresh, K.B.; Mansabdar, P. Epidermal growth factor receptor: role in human cancer. Indian J Dent Res 2017, 28, 687-694, https://doi.org/10.4103/ijdr.IJDR_534_16. London, M.; Gallo, E. Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. Cell Biol Int 2020, 44, 1267-1282, https://doi.org/10.1002/cbin.11340. Sigismund, S.; Avanzato, D.; Lanzetti, L. Emerging functions of the EGFR in cancer. Mol Oncol 2018, 12, 3-20, https://doi.org/10.1002/1878-0261.12155. Morgillo, F.; Bareschino, M.A.; Bianco, R.; Tortora, G.; Ciardiello, F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation; research in biological diversity 2007, 75, 788-799, https://doi.org/10.1111/j.1432-0436.2007.00200.x. Hobday, T.J.; Holen, K.; Donehower, R.; Camoriano, J.; Kim, G.; Picus, J.; Philip, P.; Lloyd, R.; Mahoney, M.; Erlichman, C. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. 2006, 24, 4043–4043, https://doi.org/10.1200/jco.2006.24.18_suppl.4043. Chiu, C.W.; Nozawa, H.; Hanahan, D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010, 28, 4425-4433, https://doi.org/10.1200/jco.2010.28.0198. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13, 239-246, https://doi.org/10.1016/s1470-2045(11)70393-x. Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25, 1960-1966, https://doi.org/10.1200/jco.2006.07.9525. Ako, E.; Yamashita, Y.; Ohira, M.; Yamazaki, M.; Hori, T.; Kubo, N.; Sawada, T.; Hirakawa, K. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. Oncol Rep 2007, 17, 887-893, https://doi.org/10.3892/or.17.4.887. Kim, H.G.; Tan, L.; Weisberg, E.L.; Liu, F.; Canning, P.; Choi, H.G.; Ezell, S.A.; Wu, H.; Zhao, Z.; Wang, J.; et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol 2013, 8, 2145-2150, https://doi.org/10.1021/cb400430t. Du, Z.; Lovly, C.M. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 2018, 17, 58, https://doi.org/10.1186/s12943-018-0782-4. Tan, A.C.; Vyse, S.; Huang, P.H. Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today 2017, 22, 72-84, https://doi.org/10.1016/j.drudis.2016.07.010. Annenkov, A. Receptor tyrosine kinase (RTK) signalling in the control of neural stem and progenitor cell (NSPC) development. Mol Neurobiol 2014, 49, 440-471, https://doi.org/10.1007/s12035-013-8532-5. McDonell, L.M.; Kernohan, K.D.; Boycott, K.M.; Sawyer, S.L. Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin. Hum Mol Genet 2015, 24, R60-66, https://doi.org/10.1093/hmg/ddv254. Pemmaraju, N.; Kantarjian, H.; Ravandi, F.; Cortes, J. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer 2011, 117, 3293-3304, https://doi.org/10.1002/cncr.25908. Kampa-Schittenhelm, K.M.; Heinrich, M.C.; Akmut, F.; Döhner, H.; Döhner, K.; Schittenhelm, M.M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer 2013, 12, 19, https://doi.org/10.1186/1476-4598-12-19. Weisberg, E.; Meng, C.; Case, A.E.; Sattler, M.; Tiv, H.L.; Gokhale, P.C.; Buhrlage, S.J.; Liu, X.; Yang, J.; Wang, J.; et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol 2019, 187, 488-501, https://doi.org/10.1111/bjh.16092. Zhou, F.; Ge, Z.; Chen, B. Quizartinib (AC220): a promising option for acute myeloid leukemia. Drug Des Devel Ther 2019, 13, 1117-1125, https://doi.org/10.2147/dddt.S198950. Cortes, J.E.; Khaled, S.; Martinelli, G.; Perl, A.E.; Ganguly, S.; Russell, N.; Krämer, A.; Dombret, H.; Hogge, D.; Jonas, B.A.; et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology 2019, 20, 984-997, https://doi.org/10.1016/s1470-2045(19)30150-0. Müller, A.; Florek, M.J.S.M.i.O. 5-azacytidine/Azacitidine. 2010, 159–170. Götze, K.; Müller-Thomas, C.; Peschel, C. The role of azacitidine in the management of myelodysplastic syndromes (MDS). Cancer Manag Res 2009, 1, 119-130, https://doi.org/10.2147/cmr.s4721. Scott, L.J. Azacitidine: A review in myelodysplastic syndromes and acute myeloid leukaemia. Drugs 2016, 76, 889-900, https://doi.org/10.1007/s40265-016-0585-0. Murthy, V.; Kapuge, N.; Kartsios, C.; Ewing, J.; Xenou, E.; Kaparou, M.; Shereef, E.; Nikolousis, E. Azacitidine improves outcome in patients with MDS and AML with high risk cytogenetics - a single center experience. Blood 2018, 132, 5529-5529, https://doi.org/10.1182/blood-2018-99-109774. Saba, H.I. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007, 3, 807-817. Ma, J.; Hou, Y.; Xia, J.; Zhu, X.; Wang, Z.P. Tumor suppressive role of rottlerin in cancer therapy. Am J Transl Res 2018, 10, 3345-3356. Juneja, M.; Kobelt, D.; Walther, W.; Voss, C.; Smith, J.; Specker, E.; Neuenschwander, M.; Gohlke, B.O.; Dahlmann, M.; Radetzki, S.; et al. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1. PLoS Biol 2017, 15, e2000784, https://doi.org/10.1371/journal.pbio.2000784. Wang, L.; Hou, Y.; Yin, X.; Su, J.; Zhao, Z.; Ye, X.; Zhou, X.; Zhou, L.; Wang, Z. Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells. Oncotarget 2016, 7, 69770-69782, https://doi.org/10.18632/oncotarget.11974. Jane, E.P.; Premkumar, D.R.; Pollack, I.F. Coadministration of Sorafenib with Rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. Journal of Pharmacology and Experimental Therapeutics 2006, 319, 1070-1080, https://doi.org/10.1124/jpet.106.108621. Lu, W.; Lin, C.; Li, Y. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells. Cell Signal 2014, 26, 1303-1309, https://doi.org/10.1016/j.cellsig.2014.02.018.